Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

Sandro Pignata, Sabino De Placido, Rosalbino Biamonte, Giovanni Scambia, Giovanni Di Vagno, Giuseppe Colucci, Antonio Febbraro, Marco Marinaccio, Alessandra Vernaglia Lombardi, Luigi Manzione, Giacomo Cartenì, Mario Nardi, Saverio Danese, Maria Rosaria Valerio, Andrea de Matteis, Bruno Massidda, Giampietro Gasparini, Massimo Di Maio, Carmela Pisano, Francesco Perrone

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods: 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the National Cancer Institute of Naples after the end of the trial). All patients received carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between 1998 and 2003. Data were collected between May and September 2004. Residual sensory and motor neurotoxicity were coded according to the National Cancer Institute - Common Toxicity Criteria. Results: 55 patients (46%) did not experience any grade of neurological toxicity during chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients (54%) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available for 60 of them. Fourteen out of 60 patients (23%) referred residual neuropathy at the most recent follow-up visit, after a median follow up of 18 months (range, 7-58 months): 12 patients had grade 1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor neuropathy. The remaining 46/60 patients (77%) had no residual neuropathy at the moment of interview: recovery from neurotoxicity had occurred in the first 2 months after the end of chemotherapy in 22 (37%), between 2 and 6 months in 15 (25%), or after more than 6 months in 9 patients (15%). Considering all 120 treated patients, there was a 15% probability of persistent neurological toxicity 6 months after the end of chemotherapy. Conclusions: A significant proportion of patients with advanced ovarian cancer treated with first-line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken into account before considering re-treatment with the same agents in sensitive recurrent disease.

Original languageEnglish
Article number5
JournalBMC Cancer
Volume6
DOIs
Publication statusPublished - Jan 7 2006

Fingerprint

Carboplatin
Paclitaxel
Ovarian Neoplasms
Multicenter Studies
Retrospective Studies
Drug Therapy
National Cancer Institute (U.S.)
Topotecan
Peripheral Nervous System Diseases
Therapeutics
Platinum
Area Under Curve

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel : The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. / Pignata, Sandro; De Placido, Sabino; Biamonte, Rosalbino; Scambia, Giovanni; Di Vagno, Giovanni; Colucci, Giuseppe; Febbraro, Antonio; Marinaccio, Marco; Lombardi, Alessandra Vernaglia; Manzione, Luigi; Cartenì, Giacomo; Nardi, Mario; Danese, Saverio; Valerio, Maria Rosaria; de Matteis, Andrea; Massidda, Bruno; Gasparini, Giampietro; Di Maio, Massimo; Pisano, Carmela; Perrone, Francesco.

In: BMC Cancer, Vol. 6, 5, 07.01.2006.

Research output: Contribution to journalArticle

Pignata, S, De Placido, S, Biamonte, R, Scambia, G, Di Vagno, G, Colucci, G, Febbraro, A, Marinaccio, M, Lombardi, AV, Manzione, L, Cartenì, G, Nardi, M, Danese, S, Valerio, MR, de Matteis, A, Massidda, B, Gasparini, G, Di Maio, M, Pisano, C & Perrone, F 2006, 'Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study', BMC Cancer, vol. 6, 5. https://doi.org/10.1186/1471-2407-6-5
Pignata, Sandro ; De Placido, Sabino ; Biamonte, Rosalbino ; Scambia, Giovanni ; Di Vagno, Giovanni ; Colucci, Giuseppe ; Febbraro, Antonio ; Marinaccio, Marco ; Lombardi, Alessandra Vernaglia ; Manzione, Luigi ; Cartenì, Giacomo ; Nardi, Mario ; Danese, Saverio ; Valerio, Maria Rosaria ; de Matteis, Andrea ; Massidda, Bruno ; Gasparini, Giampietro ; Di Maio, Massimo ; Pisano, Carmela ; Perrone, Francesco. / Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel : The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. In: BMC Cancer. 2006 ; Vol. 6.
@article{7888ec1126ad4ecdaa477ce45686823a,
title = "Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study",
abstract = "Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods: 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the National Cancer Institute of Naples after the end of the trial). All patients received carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between 1998 and 2003. Data were collected between May and September 2004. Residual sensory and motor neurotoxicity were coded according to the National Cancer Institute - Common Toxicity Criteria. Results: 55 patients (46{\%}) did not experience any grade of neurological toxicity during chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients (54{\%}) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available for 60 of them. Fourteen out of 60 patients (23{\%}) referred residual neuropathy at the most recent follow-up visit, after a median follow up of 18 months (range, 7-58 months): 12 patients had grade 1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor neuropathy. The remaining 46/60 patients (77{\%}) had no residual neuropathy at the moment of interview: recovery from neurotoxicity had occurred in the first 2 months after the end of chemotherapy in 22 (37{\%}), between 2 and 6 months in 15 (25{\%}), or after more than 6 months in 9 patients (15{\%}). Considering all 120 treated patients, there was a 15{\%} probability of persistent neurological toxicity 6 months after the end of chemotherapy. Conclusions: A significant proportion of patients with advanced ovarian cancer treated with first-line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken into account before considering re-treatment with the same agents in sensitive recurrent disease.",
author = "Sandro Pignata and {De Placido}, Sabino and Rosalbino Biamonte and Giovanni Scambia and {Di Vagno}, Giovanni and Giuseppe Colucci and Antonio Febbraro and Marco Marinaccio and Lombardi, {Alessandra Vernaglia} and Luigi Manzione and Giacomo Carten{\`i} and Mario Nardi and Saverio Danese and Valerio, {Maria Rosaria} and {de Matteis}, Andrea and Bruno Massidda and Giampietro Gasparini and {Di Maio}, Massimo and Carmela Pisano and Francesco Perrone",
year = "2006",
month = "1",
day = "7",
doi = "10.1186/1471-2407-6-5",
language = "English",
volume = "6",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel

T2 - The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

AU - Pignata, Sandro

AU - De Placido, Sabino

AU - Biamonte, Rosalbino

AU - Scambia, Giovanni

AU - Di Vagno, Giovanni

AU - Colucci, Giuseppe

AU - Febbraro, Antonio

AU - Marinaccio, Marco

AU - Lombardi, Alessandra Vernaglia

AU - Manzione, Luigi

AU - Cartenì, Giacomo

AU - Nardi, Mario

AU - Danese, Saverio

AU - Valerio, Maria Rosaria

AU - de Matteis, Andrea

AU - Massidda, Bruno

AU - Gasparini, Giampietro

AU - Di Maio, Massimo

AU - Pisano, Carmela

AU - Perrone, Francesco

PY - 2006/1/7

Y1 - 2006/1/7

N2 - Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods: 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the National Cancer Institute of Naples after the end of the trial). All patients received carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between 1998 and 2003. Data were collected between May and September 2004. Residual sensory and motor neurotoxicity were coded according to the National Cancer Institute - Common Toxicity Criteria. Results: 55 patients (46%) did not experience any grade of neurological toxicity during chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients (54%) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available for 60 of them. Fourteen out of 60 patients (23%) referred residual neuropathy at the most recent follow-up visit, after a median follow up of 18 months (range, 7-58 months): 12 patients had grade 1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor neuropathy. The remaining 46/60 patients (77%) had no residual neuropathy at the moment of interview: recovery from neurotoxicity had occurred in the first 2 months after the end of chemotherapy in 22 (37%), between 2 and 6 months in 15 (25%), or after more than 6 months in 9 patients (15%). Considering all 120 treated patients, there was a 15% probability of persistent neurological toxicity 6 months after the end of chemotherapy. Conclusions: A significant proportion of patients with advanced ovarian cancer treated with first-line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken into account before considering re-treatment with the same agents in sensitive recurrent disease.

AB - Background: Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods: 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated at the National Cancer Institute of Naples after the end of the trial). All patients received carboplatin (AUC 5) plus paclitaxel (175 mg/m2) every 3 weeks for 6 cycles, completing treatment between 1998 and 2003. Data were collected between May and September 2004. Residual sensory and motor neurotoxicity were coded according to the National Cancer Institute - Common Toxicity Criteria. Results: 55 patients (46%) did not experience any grade of neurological toxicity during chemotherapy and of these none had signs of neuropathy during follow-up. The other 65 patients (54%) had chemotherapy-induced neurotoxicity during treatment and follow-up data are available for 60 of them. Fourteen out of 60 patients (23%) referred residual neuropathy at the most recent follow-up visit, after a median follow up of 18 months (range, 7-58 months): 12 patients had grade 1 and 2 patients grade 2 peripheral sensory neuropathy; 3 patients also had grade 1 motor neuropathy. The remaining 46/60 patients (77%) had no residual neuropathy at the moment of interview: recovery from neurotoxicity had occurred in the first 2 months after the end of chemotherapy in 22 (37%), between 2 and 6 months in 15 (25%), or after more than 6 months in 9 patients (15%). Considering all 120 treated patients, there was a 15% probability of persistent neurological toxicity 6 months after the end of chemotherapy. Conclusions: A significant proportion of patients with advanced ovarian cancer treated with first-line carboplatin/paclitaxel suffer long-term residual neuropathy. This issue should be carefully taken into account before considering re-treatment with the same agents in sensitive recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=30644462055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644462055&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-6-5

DO - 10.1186/1471-2407-6-5

M3 - Article

C2 - 16398939

AN - SCOPUS:30644462055

VL - 6

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 5

ER -